Blonde L, Brunton SA, Chava P, Zhou R, Meyers J, Davis KL, Dalal MR, Digenio A. Achievement of target A1C <7.0% (<53 mmol/mol) by U.S. type 2 diabetes patients treated with basal insulin in both randomized controlled trials and clinical practice. Diabetes Spectr. 2018 Nov;31(4). doi: 10.2337/ds17-0082
Loughlin AM, Qiao Q, Nunes AP, Ezzy SM, Yochum L, Clifford CR, Gately RV, Dore DD, Seeger JD. Effectiveness and tolerability of therapy with once-weekly exenatide versus basal insulin among injectable-naive patients with type 2 diabetes in a real-world setting in the United States. Diabetes Spectr. 2018 May;31(2):129-37. doi: 10.2337/ds16-0081
Setji T, Hopkins TJ, Jimenez M, Manning E, Shaughnessy M, Schroeder R, Mendoza-Lattes S, Spratt S, Westover J, Aronson S. Rationalization, development, and implementation of a preoperative diabetes optimization program designed to improve perioperative outcomes and reduce cost. Diabetes Spectr. 2017 Aug;30(3):217-23.
Thijssen JJJ, Bregantini D. Costly sequential experimentation and project valuation with an application to health technology assessment. J Econ Dyn Control. 2017 Apr 1;77:202-29. doi: 10.1016/j.jedc.2017.01.016